• 1
    Ferasin L, Sturgess CP, Cannon MJ, et al. Feline idiopathic cardiomyopathy: A retrospective study of 106 cats (1994-2001). J Feline Med Surg 2003;5:151159.
  • 2
    Fox P, Liu S, Maron B. Echocardiographic assessement of spontaneously occurring feline hypertrophic cardiomyopathy. An animal model of human disease. Circulation 1995;92:26452651.
  • 3
    Maron M, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295303.
  • 4
    Rush J, Freeman L, Fenollosa N, et al. Population and survival characteristics of cats with hypertrophic cardiomyopathy: 260 cases (1990-1999). J Am Vet Med Assoc 2002;220(2):202207.
  • 5
    Payne J, Luis Fuentes V, Boswood A, et al. Population characteristics and survival in 127 referred cats with hypertrophic cardiomyopathy (1997 to 2005). J Small Anim Pract 2010;51(10):540547.
  • 6
    Schober KE, Zientek J, Li X, et al. Effect of treatment with atenolol on 5-year survival in cats with preclinical (asymptomatic) hypertrophic cardiomyopathy. J Vet Cardiol 2013;15:93104.
  • 7
    Fox P. Evidence for or against efficacy of beta-blockers and aspirin for managment of feline cardiomyopathies. Vet Clin North Am Small Anim Pract 1991;21(5):10111022.
  • 8
    Riccioni G. Ivabradine: From molecular basis to clinical effectiveness. Adv Ther 2010;27(3):160167.
  • 9
    Riesen S, Schober K, Smith D, et al. Effects of ivabradine on heart rate and left ventricular function in healthy cats and cats with hypertrophic cardiomyopathy. Am J Vet Res 2011;73:202212.
  • 10
    Riesen S, Schober K, Cervenec R, et al. Comparison of the effects of ivabradine and atenolol on heart rate and echocardiographic variables of left heart function in healthy cats. J Vet Intern Med 2011;25:469476.
  • 11
    Riesen S, Ni W, Carnes C, et al. Pharmacokinetics of oral ivabradine in healthy cats. J Vet Pharmacol Ther 2011;34(5):469475.
  • 12
    Cober R, Schober K, Buffington C, et al. Pharmacodynamic effects of ivabradine, a negative chronotropic agent, in healthy cats. J Vet Cardiol 2011;13(4):231242.
  • 13
    Riesen S, Schober K, Cervenec R, et al. Effects of treatment with ivabradine and atenolol on reproducibility of echocardiographic indices of left heart size and function in healthy cats. J Vet Cardiol 2012;14(2):323332.
  • 14
    Klues H, Roberts W, Maron B. Morphological determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. Circulation 1993;87:15701579.
  • 15
    Thomas W, Gaber C, Jacobs GJ, et al. Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. J Vet Intern Med 1993;7:247252.
  • 16
    Bonagura J. Feline echocardiography. J Feline Med Surg 2000;2(3):147151.
  • 17
    Brown S, Atkins C, Bagley R, et al. Guidelines for the identification, evaluation, and managment of systemic hypertension in dogs and cats. J Vet Intern Med 2007;21(3):542558.
  • 18
    Marwick TH, Nakatani S, Haluska B, et al. Provocation of latent left ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic cardiomyopathy. Am J Cardiol 1995;75(12):805809.
  • 19
    Sheikh K, Pearce F, Kisslo J. Use of Doppler echocardiography and amyl nitrite inhalation to characterize left ventricular outflow obstruction in hypertrophic cardiomyopathy. Chest 1990;97(2):389395.
  • 20
    Helmcke F, Nanda N, Hsiung M, et al. Color Doppler assessment of mitral regurgitation with orthogonal planes. Circulation 1987;75:175183.
  • 21
    Schober K, Maerz I. Doppler echocardiographic assessment of left atrial appendage flow velocities in normal cats. J Vet Cardiol 2005;7:1525.
  • 22
    Yoganathan A, Lemmon J Jr, Kim Y, et al. A three-dimensional computational investigation of intraventricular fluid dynamics: Examination into the initiation of systolic anterior motion of the mitral valve leaflets. J Biomech Eng 1995;117(1):94102.
  • 23
    Sherrid M. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2000;36:13441354.
  • 24
    Levine RA, Vlahakes GJ, Lefebvre X, et al. Papillary muscle displacement causes systolic anterior motion of the mitral valve: Experimental validation and insights into the mechanism of subaortic obstruction. Circulation 1995;91:11891195.
  • 25
    Cape E, Simons D, Jimoh A, et al. Chordal geometry determines the shape and extent of systolic anterior motion: In vitro studies. J Am Coll Cardiol 1989;13(6):14381448.
  • 26
    Sherrid M, Pearle G, Gunsburgh D. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation 1998;97:4147.
  • 27
    Salisbury P, Cross C, Rieben P. Chorda tendinae tension. Am J Physiol 1963;205:385392.
  • 28
    Joshi S, Patel U, Yao S-S, et al. Standing and exercise Doppler echocardiography in obstructive hypertrophic cardiomyopathy: The range of gradients with upright activity. J Am Soc Echocardiogr 2011;24(1):7582.
  • 29
    Cabrera-Bueno F, García-Pinilla J, Gómez-Doblas J, et al. Beta-blocker therapy for dynamic left ventricular outflow tract obstruction induced by exercise. Int J Cardiol 2007;117(2):222226.